"Enzyme Replacement Therapy Market: A Comprehensive Industry Analysis"

Enzyme replacement therapy (ERT) is an emerging field in the treatment of rare genetic diseases caused by enzyme deficiencies. This therapy involves the replacement of the missing or deficient enzyme with a functional one through intravenous infusion. The global ERT market is expected to witness significant growth in the coming years due to the increasing prevalence of rare diseases, advancements in biotechnology and healthcare, and rising investments in research and development.
The enzyme replacement therapy market was estimated at US$ 7.93 billion in 2021 and is expected to grow at a CAGR of 8.28% during 2022-2028 to reach US$ ~13.9 billion in 2028.
The emerging trends in the ERT market include the development of novel therapies, the increasing use of combination therapies, and the growing adoption of gene therapy. Novel therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and gene editing are gaining attention as potential treatments for rare genetic diseases. Combination therapies that involve the use of multiple enzymes or enzyme replacement therapies with other treatments are also being explored to improve efficacy and outcomes.
Request a sample here:
https://www.stratviewresearch.com/Request-Sample/3156/enzyme-replacement-therapy-market.html#form
The enzyme replacement therapy market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America led the market. The presence of prominent market participants in North America, as well as well-developed healthcare infrastructure, has propelled the regional segment's rise. Furthermore, the region's embrace of sophisticated technology and increased focus on medication research are projected to promote industry growth.
The overall competitive landscape has been affected due to these mergers and acquisitions. The following are the major players in the enzyme replacement therapy market:
• AbbVie
• Actelion (Janssen)
• Alexion Pharmaceuticals Inc.
• Allergan plc
• Amicus Therapeutics, Inc.
• Biomarin Pharmaceutical Inc.
• Horizon Pharma Public Limited Company
• Protalix Biotherapeutics
• Recordati Rare Diseases
• Shire Plc
• Sanofi S.A
In conclusion, the enzyme replacement therapy market is expected to witness significant growth during the forecast period due to the increasing prevalence of rare diseases and genetic disorders, rising geriatric population, and growing demand for personalized medicine.